Shree Vishwamitra Ayurved Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 25-07-2024
- Paid Up Capital ₹ 1.00 M
as on 25-07-2024
- Company Age 28 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 8.66 M
as on 25-07-2024
- Satisfied Charges ₹ 1.45 M
as on 25-07-2024
- Revenue 18.41%
(FY 2023)
- Profit -20.76%
(FY 2023)
- Ebitda 14.97%
(FY 2023)
- Net Worth 11.78%
(FY 2023)
- Total Assets -2.91%
(FY 2023)
About Shree Vishwamitra Ayurved Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹8.66 M. The company has closed loans amounting to ₹1.45 M, as per Ministry of Corporate Affairs (MCA) records.
Kalyan Keskar and Varsha Keskar serve as directors at the Company.
- CIN/LLPIN
U24231GJ1996PTC029318
- Company No.
029318
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Apr 1996
- Date of AGM
16 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Shree Vishwamitra Ayurved Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kalyan Keskar  | Director | 11-Apr-1996 | Current |
| Varsha Keskar | Director | 11-Apr-1996 | Current |
Financial Performance of Shree Vishwamitra Ayurved Pharmaceuticals.
Shree Vishwamitra Ayurved Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 18.41% increase. The company also saw a substantial fall in profitability, with a 20.76% decrease in profit. The company's net worth Soared by an impressive increase of 11.78%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Shree Vishwamitra Ayurved Pharmaceuticals?
In 2023, Shree Vishwamitra Ayurved Pharmaceuticals had a promoter holding of 10.00% and a public holding of 90.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 27 May 2006 | ₹8.66 M | Open |
Central Bank Of India Creation Date: 11 Jul 2009 | ₹1.45 M | Satisfied |
How Many Employees Work at Shree Vishwamitra Ayurved Pharmaceuticals?
Unlock and access historical data on people associated with Shree Vishwamitra Ayurved Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Shree Vishwamitra Ayurved Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Shree Vishwamitra Ayurved Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
